Patents by Inventor Hugh Sampson
Hugh Sampson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7820175Abstract: The present invention provides herbal formulas, and compositions thereof, that can treat or reduce the severity, intensity, or duration of food allergy and food allergy related symptoms. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutically acceptable carriers or excipients, and may be administered prior to, during, or after the development of food allergy-related symptoms in a patient in need thereof.Type: GrantFiled: March 14, 2005Date of Patent: October 26, 2010Assignee: Herbal Spring, LLCInventors: Xiu-Min Li, Hugh A. Sampson
-
Publication number: 20100166802Abstract: The present invention provides methods and compositions for treating or preventing allergic reactions, particularly anaphylactic reactions. Methods of the present invention involve administering microorganisms to allergic subjects, where the microorganisms contain a recombinant version of the protein allergen. The recombinant version can be wild-type or may include mutations within IgE epitopes of the protein allergen. Preferably the compositions are administered rectally. Particularly preferred microorganisms are bacteria such as E. coli. Any allergen may be used in the inventive methods. Particularly preferred allergens are anaphylactic allergens including protein allergens found in foods, venoms, drugs and latex. The inventive compositions and methods are demonstrated in the treatment of peanut-induced anaphylaxis.Type: ApplicationFiled: October 2, 2009Publication date: July 1, 2010Inventors: Michael J. Caplan, H. Kim Bottomly, Howard B. Sosin, A. Wesley Burks, Hugh A. Sampson
-
Publication number: 20090111702Abstract: The present invention is directed to materials and methods that may be used in diagnosing and/or characterizing allergies. More specifically, the specification describes methods and compositions for making and using a plurality of peptides having allergen epitopes that may be used in immunoassays e.g., microarray-based immunoassays to predict the severity of an allergic response.Type: ApplicationFiled: March 22, 2005Publication date: April 30, 2009Applicant: MOUNT SINAI SCHOOL OF MEDICINE Office of Industrial LiasonInventors: Hugh A. Sampson, Wayne G. Shreffler, Kirsten Beyer
-
Patent number: 7485708Abstract: It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by masking the site with a compound that prevents IgE binding or by altering as little as a single amino acid within the protein, most typically a hydrophobic residue towards the center of the IgE binding epitope, to eliminate IgE binding. The method allows the protein to be altered as minimally as possible, other than within the IgE-binding sites, while retaining the ability of the protein to activate T cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The examples use peanut allergens to demonstrate alteration of IgE binding sites. The critical amino acids within each of the IgE binding epitopes of the peanut protein that are important to immunoglobulin binding have been determined.Type: GrantFiled: August 26, 2002Date of Patent: February 3, 2009Assignee: University of ArkansasInventors: A. Wesley Burks, Jr., Gary A. Bannon, Hugh A. Sampson, Ricki M. Helm, J. Steven Stanley, Patrick A. Rabjohn
-
Publication number: 20080317878Abstract: The present invention provides herbal formulas, and compositions thereof, that can treat or reduce the severity, intensity, or duration of food allergy and food allergyrelated symptoms. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutically acceptable carriers or excipients, and may be administered prior to, during, or after the development of food allergy-related symptoms in a patient in need thereof.Type: ApplicationFiled: March 14, 2005Publication date: December 25, 2008Inventors: Xiu-Min Li, Hugh A. Sampson
-
Publication number: 20080254484Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.Type: ApplicationFiled: May 30, 2008Publication date: October 16, 2008Inventors: Murtaza E. Alibhai, James D. Astwood, Charles A. McWherter, Hugh A. Sampson
-
Publication number: 20080213298Abstract: The present invention provides herbal formulas, and compositions thereof, that can treat or reduce the severity, intensity, or duration of asthma and asthma-related symptoms. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutically acceptable carriers or excipients, and may be administered prior to, during, or after the development of asthmatic symptoms in a patient in need thereof.Type: ApplicationFiled: March 14, 2005Publication date: September 4, 2008Inventors: Xiu-Min Li, Hugh A. Sampson, Ming-Chun Weng
-
Patent number: 7381556Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.Type: GrantFiled: June 28, 2007Date of Patent: June 3, 2008Assignee: Monsanto Technology LLCInventors: Murtaza F. Alibhai, James D. Astwood, Charles A. McWherter, Hugh A. Sampson
-
Publication number: 20080010700Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.Type: ApplicationFiled: June 28, 2007Publication date: January 10, 2008Inventors: Murtaza Alibhai, James Astwood, Charles McWherter, Hugh Sampson
-
Publication number: 20070213507Abstract: It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by masking the site with a compound that prevents IgE binding or by altering as little as a single amino acid within the protein, most typically a hydrophobic residue towards the center of the IgE-binding epitope, to eliminate IgE binding. The method allows the protein to be altered as minimally as possible, other than-within the IgE-binding sites, while retaining the ability of the protein to activate T cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity The examples use peanut allergens to demonstrate alteration of IgE binding sites. The critical amino acids within each of the IgE binding epitopes of the peanut protein that are important to immunoglobulin binding have been determined.Type: ApplicationFiled: January 10, 2006Publication date: September 13, 2007Inventors: A. Burks, Gary Bannon, Hugh Sampson, Ricki Helm, Gael Cockrell, J. Stanley, Nina King
-
Patent number: 7238511Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.Type: GrantFiled: September 7, 2005Date of Patent: July 3, 2007Assignee: Monsanto Technology LLCInventors: Murtaza F. Alibhai, James D. Astwood, Charles A. McWherter, Hugh A. Sampson
-
Publication number: 20060206962Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.Type: ApplicationFiled: September 7, 2005Publication date: September 14, 2006Inventors: Murtaza Alibhai, James Astwood, Charles McWherter, Hugh Sampson
-
Patent number: 6943002Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of palatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.Type: GrantFiled: September 9, 2003Date of Patent: September 13, 2005Assignee: Monsanto Technology LLCInventors: Murtaza F. Alibhai, James D. Astwood, Charles A. McWherter, Hugh A. Sampson
-
Publication number: 20050063994Abstract: The present invention provides methods and compositions for treating or preventing allergic reactions, particularly anaphylactic reactions. Methods of the present invention involve administering microorganisms to allergic subjects, where the microorganisms contain a recombinant version of the protein allergen. The recombinant version can be wild-type or may include mutations within IgE epitopes of the protein allergen. Preferably the compositions are administered rectally. Particularly preferred microorganisms are bacteria such as E. coli. Any allergen may be used in the inventive methods. Particularly preferred allergens are anaphylactic allergens including protein allergens found in foods, venoms, drugs and latex. The inventive compositions and methods are demonstrated in the treatment of peanut-induced anaphylaxis.Type: ApplicationFiled: July 26, 2004Publication date: March 24, 2005Inventors: Michael Caplan, Kim Bottomly, Howard Sosin, A. Burks, Hugh Sampson
-
Publication number: 20050048576Abstract: The present invention is directed to methods for predicting or diagnosing a hazelnut-induced systemic reaction, and for methods for treating such a reaction.Type: ApplicationFiled: June 2, 2004Publication date: March 3, 2005Inventors: Hugh Sampson, Kirsten Beyer
-
Publication number: 20040216187Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding.Type: ApplicationFiled: September 9, 2003Publication date: October 28, 2004Applicant: MONSANTO TECHNOLOGY LLCInventors: Murtaza F. Alibhai, James D. Astwood, Charles A. McWherter, Hugh A. Sampson
-
Publication number: 20030202980Abstract: It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T-cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by altering as little as a single amino acid within the protein, preferably a hydrophobic residue towards the center of the IgE epitope, to eliminate IgE binding. Additionally or alternatively a modified allergen with reduced IgE binding may be prepared by disrupting one or more of the disulfide bonds that are present in the natural allergen. The disulfide bonds may be disrupted chemically, e.g., by reduction and alkylation or by mutating one or more cysteine residues present in the primary amino acid sequence of the natural allergen. In certain embodiments, modified allergens are prepared by both altering one or more linear IgE eitopes and disrupting one or more disulfide bonds of the natural allergen.Type: ApplicationFiled: March 18, 2002Publication date: October 30, 2003Inventors: Michael J. Caplan, Howard B. Sosin, Hugh Sampson, Gary A. Bannon, A. Wesley Burks, Gael Cockrell, Cesar M. Compadre, Cathie Connaughton, Ricki M. Helm, Nina E. King, Randall A. Kopper, Soheila J. Maleki, Patrick A. Rabjohn, David S. Shin, J. Steven Stanley
-
Patent number: 6639054Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.Type: GrantFiled: January 5, 2001Date of Patent: October 28, 2003Assignee: Monsanto Technology LLCInventors: Murtaza F. Alibhai, James D. Astwood, Charles A. McWherter, Hugh A. Sampson
-
Publication number: 20030194399Abstract: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding.Type: ApplicationFiled: January 5, 2001Publication date: October 16, 2003Applicant: MONSANTO TECHNOLOGY LLCInventors: Murtaza F. Alibhai, James D. Astwood, Charles A. McWherter, Hugh A. Sampson
-
Patent number: 6630176Abstract: The present invention provides herbal compositions that can prevent or reduce the severity, intensity, or duration of allergic and/or asthmatic symptoms and/or can prevent or delay the development of an allergic or asthmatic response to an antigen. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutical carriers or excipients, and may be administered prior to, during, or after the development of allergic or asthmatic symptoms in sensitized individuals. Alternatively or additionally, the compositions may be administered prior to sensitization to a particular antigen; preferably substantially concurrently with exposure to the antigen.Type: GrantFiled: March 7, 2001Date of Patent: October 7, 2003Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Xiu-Min Li, Hugh A. Sampson